By informing veterinarians and pet parents about which mutations are causing their pet’s cancer to grow and spread, we intend to open up the use of precision medicine to combat canine cancer in new and more effective ways.
Vidium is dedicated to unravelling the genetic components of common and complex diseases, including cancer. As a result, the practice of medicine targeting these conditions can be more rational, more precise and more personal. Our focus is on shifting paradigms in cancer treatment to enable cures for cancer and other serious diseases in pets through programs at the intersection of personalized medicine and comparative genomics.
Providing veterinarians with the very best technology and insight to confidently diagnose and treat pets with cancer.
president and co-founder
chief scientific officer and founder
vice president of operations and co-founder
vice president of strategy, innovation and diagnostics
head of clinical curation
head of veterinary affairs
liquid biopsy lead
clinical relations specialist
cancer genomic scientist
DVM, PhD, DACVIM
DVM, MS, DACVIM (Oncology)
DVM, MS, PhD
The Translational Genomics Research Institute (TGen, an Affiliate of City of Hope) is a leader in the genomics revolution. Begun by Dr. Jeffrey M. Trent, the founding Scientific Director of the Human Genome Project, this world-class research institute explores the most advanced areas of genetics in human and animal health. As a subsidiary of TGen, Vidium Animal Health® benefits from the incredible knowledge and research of TGen scientists.